Sanofi Consumer Healthcare Shares Jump 10.5% as Q2FY25 Profit Rises 21% QoQ; Revenue Up 28% YoY

Mumbai, August 5, 2025 – Sanofi Consumer Healthcare India Ltd (NSE: SANOFICONR, BSE: 544250) saw its stock rally by 10.51% at 2:30 PM IST, climbing ₹514 to hit ₹5,308, following the announcement of strong Q2FY25 results. The surge comes on the back of robust revenue growth, margin expansion, and successful product relaunches.

Q2FY25 Results Boost Market Sentiment

Sanofi Consumer Healthcare reported a 28% YoY increase in Q2FY25 revenue to ₹2,209 million, while profit after tax (PAT) jumped 21% sequentially to ₹607 million. The growth was driven by strong export operations, the relaunch of key products, and a lean cost structure.

Key Financials (₹ in million)

• Revenue from operations rose to ₹2,209 million in Q2FY25, up 28.2% year-on-year and 28% sequentially from ₹1,726 million in Q1FY25.
• Total income stood at ₹2,265 million, registering a 30.9% increase YoY and 27.4% growth QoQ.
• Profit before tax (PBT) surged to ₹789 million, more than doubling from ₹389 million in Q2FY24. This is a 102.8% YoY jump and 18.1% growth QoQ.
• Profit after tax (PAT) came in at ₹607 million, up 109.3% YoY and 21.4% QoQ, compared to ₹290 million in Q2FY24 and ₹500 million in Q1FY25.
• Earnings per share (EPS) for the quarter stood at ₹26.36, improving from ₹21.69 in the previous quarter and ₹12.58 in Q2FY24.

Segment & Strategic Performance

• Sales of Products in Q2FY25 stood at ₹2,023 million, up from ₹1,586 million in Q1FY25.
• Export operations commenced during the quarter, adding a new growth lever.
• Relaunched products: Combiflam Suspension and Depura 60K.
• New launch: Allegra D, targeted at the allergy market.

Exceptional Gain

The company reported an exceptional income of ₹66 million in Q2FY25, driven by the reversal of excess demerger-related provisions.

Management Commentary

Himanshu Bakshi, Managing Director, stated: “Our commitment to delivering high-quality, science-backed products continues to anchor our growth strategy, driven by a focused portfolio, research-led innovation, and an agile organization. The quarter reflects the outcomes of a focused approach, with the successful relaunch of previously recalled products and expansion into international markets.”

Outlook

Sanofi Consumer Healthcare India continues to gain traction in the domestic and international markets with a sharpened focus on its consumer-centric product lineup. With strong product pipelines, exports picking up, and the re-entry of legacy brands, the company appears poised for sustained growth.

Sanofi Consumer Healthcare India Stock Performance

Sanofi Consumer Healthcare India shares are trading at ₹5,297.80, which is a 10.51% gain on August 5, 2025, at 2:30 PM IST. Sanofi Consumer Healthcare India shares have witnessed an 8.04% gain in the last year, a 7.93% gain in the year-to-date, and dipped 1.41% in the previous month.

Shares of Sanofi Consumer Healthcare India opened at ₹5,065 and climbed to an intraday high of ₹5,512 on Tuesday, staying close to their 52-week high of ₹5,894.50. At current levels, the company commands a market capitalisation of ₹12,180 crore, trading at a price-to-earnings (P/E) ratio of 72.35. Sanofi continues to offer consistent dividends, with a quarterly payout of ₹13.75 per share and a dividend yield of 1.04%. Over the past year, the stock has traded between ₹4,211.55 and ₹5,894.50.

About Sanofi Consumer Healthcare India

Sanofi Consumer Healthcare India Limited (SCHIL) is a listed entity focused on consumer healthcare following its demerger from Sanofi India. Effective from June 1, 2024, the company now operates independently with key brands such as Avil, Allegra, Depura, and Combiflam. It is part of Opal JVco S.a.r.l., a global joint venture between Sanofi and Clayton, Dubilier & Rice.

REF: https://nsearchives.nseindia.com/corporate/SANOFICONSUMER_04082025201945_BM_Outcome_04082025_Q2_ns.pdf

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations